Farabursen

RNA / oligonucleotide

Also known as CYX082

Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.

—no registered trials

Evidence outlook

No clinical trials on ClinicalTrials.gov

No clinical trial of this drug is registered on ClinicalTrials.gov, so there is nothing to grade. Studies run outside that registry are not tracked here.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded.

No registered studies found. Not yet ingested, or none registered.

Competitive landscape

This drug's own stage for Autosomal Dominant Polycystic Kidney Disease: Stage not on record. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Farabursen: this drugStage not on recordRNA / oligonucleotidemiR-17not yet gradedNo reviewed efficacy summary in this indication
Tolvaptan (Jynarque)ApprovedSmall moleculeVasopressin V2 receptorPartial signal
NCT02160145: Annualized change in eGFR (REPRISE trial): -2.34 mL/min/1.73m2/year tolvaptan vs -3.61 mL/min/1.73m2/year placebo; difference 1.27 mL/min/1.73m2/year (95% CI 0.86-1.68), 35% reduction in decline, P<0.001
NCT00428948: Total kidney volume growth over 36 months: tolvaptan 2.78% per year vs placebo 5.61% per year; difference -2.71 percentage points per year (95% CI -3.27 to -2.15), p<0.0001 (n=819 and 458 analysed) (CT.gov posted results).
VX-407Phase 2Small moleculePolycystin-1 (PKD1 variants)not yet gradedNo reviewed efficacy summary in this indication
AZD1613Phase 1Monoclonal antibodyPAPP-Anot yet gradedNo reviewed efficacy summary in this indication
GSK4771261Phase 1Monoclonal antibody—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.